Current drug therapy for prostate cancer: an overview

Stewart, A.B., Lwaleed, B.A., Douglas, D.A. and Birch, B.R. (2005) Current drug therapy for prostate cancer: an overview. Current Medicinal Chemistry - Anti-Cancer Agents, 5 (6), 603-612. (doi:10.2174/156801105774574658).

Record type: Article

Abstract

Prostate cancer is the most common cancer amongst men in the USA and the second most common malignant cause of male death worldwide after lung cancer. The life time risk of having microscopic evidence of prostate cancer for a 50 year old man in 42%. Prostate cancer is thus becoming an increasingly significant global health problem in terms of mortality, morbidity, as well as economically. This review, discusses current medical therapeutic options for prostate cancer including traditional treatments using luteinising hormone releasing analogues (LHRH), anti-androgens and estrogen treatments, and the use of novel drugs directed against molecular targets considered important in oncogenesis and metastasis. Prostate cancer chemoprevention using 5_-reductase inhibitors and the role of gene therapy are also considered.

This record has no associated files available for download.